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Abstract
Background: Intraoperative and postoperative management of cardiac surgery patients is complex, involving the
application of differential vasopressors and volume therapy. It has been shown that a positive fluid balance has a
major impact on postoperative outcome. Today, the advantages and disadvantages of buffered crystalloid solutes
are a topic of controversy, with no consensus being reached so far. The use of hypertonic saline (HS) has shown
promising results with respect to lower total fluid balance and postoperative weight gain in critically ill patients in
preliminary studies. However, collection of more data on HS in critically ill patients seems warranted. This preliminary
study aims to investigate whether fluid resuscitation using HS in patients following cardiac surgery results in less total
fluid volume being administered.
Methods: In a prospective double-blind randomised controlled clinical trial, we aim to recruit 96 patients undergoing
elective cardiac surgery for ischaemic and/or valvular heart disease. After postoperative admission to the intensive care
unit (ICU), patients will be randomly assigned to receive 5ml/kg ideal body weight HS (7.3% NaCl) or normal saline (NS,
0.9% NaCl) infused within 60min. Blood and urine samples will be collected preoperatively and postoperatively up to
day 6 to assess changes in renal, cardiac, inflammatory, acid-base, and electrolyte parameters. Additionally, we
will perform renal ultrasonography studies to assess renal blood flow before, during, and after infusion, and
we will measure total body water using preoperative and postoperative body composition analysis (bioimpedance).
Patients will be followed up for 90 days.
Discussion: The key objective of this study is to assess the cumulative amount of fluid administered in the intervention
(HS) group versus control (NS) group during the ICU stay. In this preliminary, prospective, randomised controlled
clinical trial we will test the hypothesis that use of HS results in less total fluids infused and less postoperative
weight gain when compared to the standard of intensive care in cardiac surgery patients.
Trial registration: ClinicalTrials.gov, NCT03280745. Registered on 12 September 2017.
Keywords: Hypertonic saline, Normal saline, Fluid resuscitation, Cardiac surgery, Cardiosurgery, Ischaemic heart
disease, Valvular heart disease, Fluid balance, Critical illness, ICU
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Background
Cardiovascular surgery for ischaemic or valvular heart
disease has become a major approach in daily practice in
industrialised countries, with more than 100,000 surger-
ies performed in Germany per year [1]. Perioperative
management of cardiac surgery patients remains com-
plex; challenges for anaesthesiologists and intensive care
physicians arise from specific characteristics of the
underlying cardiac disease, the complexity of the surgical
intervention, and the pathophysiological impact of extra-
corporeal circulation [2]. Furthermore, cardiac surgery
alters fluid balance significantly, generates a systemic in-
flammatory response that increases oxygen consump-
tion, and is associated with changes in cardiac output
and oxygen delivery [3, 4].
Recommendations for fluid strategies have changed
considerably in recent years [1]. Despite the ongoing de-
bate over the role of colloids in patients undergoing car-
diac surgery [4–6], growing doubt with regard to the
safety and efficiency of colloid solutes has led to in-
creased use of crystalloid solutes [1, 7, 8]. According to a
recent large multicentre survey conducted in Germany,
crystalloids are considered the fluid of choice for intra-
operative fluid therapy, cardiopulmonary bypass circuit
priming, and post-surgery intensive care [1].
Critically ill patients, and especially patients undergo-
ing cardiac surgery, receive considerable amounts of
intravenously administered fluid [9, 10], which often re-
sults in fluid overload. Despite common perception, fluid
overload is not a benign occurrence, with mounting data
demonstrating an association with prolonged intensive
care unit (ICU) and hospital length of stay and increased
mortality [11, 12]. In addition, fluid overload (defined as
a ≥ 10% increase in body weight) [13] has been associ-
ated with increased perioperative complications [14, 15]
and decreased gastrointestinal function [9, 16].
Fluid resuscitation using a bolus or continuous infu-
sion of hypertonic saline (HS) has been used for more
than 30 years [9, 17, 18]. HS expands intravascular vol-
ume by shifting fluid from the extravascular space [19,
20], thus increasing preload [21, 22]. Compared to con-
ventional artificial plasma expanders or human plasma,
HS is considered inexpensive, rapidly available, and
without risk of anaphylaxis or transmission of infectious
disease [22]. Despite potential physiological advantages,
HS has been used less in recent years, which may at
least partially be due to previous use of mixed solutions
(e.g. HS with colloids). Currently, studies assessing the
use of HS for fluid resuscitation in critical illness are
scarce and heterogeneous regarding effects on clinical
outcomes. However, several studies have shown that in-
fusion of HS results in less volume administered [22–
26], favourable total fluid balance [22–24, 26], and less
weight gain after surgical procedures when compared to
normally used crystalloids [23, 27]. Thus, fluid resuscita-
tion with HS infusion may provide benefits in selected
critically ill patients. In patients undergoing cardiac sur-
gery, only one study was conducted with the primary
outcome of fluid status after surgery [27]. It showed
promising results in terms of less total volume infused,
less postoperative weight gain, and increased postopera-
tive diuresis. However, these findings await confirmation
in a larger population.
We propose a preliminary prospective, single-centre,
randomised controlled clinical trial on the use of HS
(7.3% NaCl) versus NS (0.9% NaCl) in addition to con-
ventional fluid resuscitation with lactated Ringer’s solu-
tion in patients after cardiac surgery. We will test the
hypothesis that use of HS results in less total volume in-
fused and less postoperative weight gain when compared
to fluid resuscitation with the standard of care in pa-
tients after cardiac surgery.
Objectives
Primary objective
This preliminary study aims to investigate whether fluid
resuscitation using HS in patients following cardiac sur-
gery results in less total fluid volume administered.
Secondary objectives
Secondary objectives are to investigate whether the use of
HS results in less postoperative weight gain, reduced cumu-
lative vasopressor dose and shorter time on vasopressors
after cardiac surgery, as well as increased urinary output.
Exploratory outcomes
Further, we will assess whether use of HS results in a
change in acid-base parameters and electrolyte levels as
well as inflammatory/immune, cardiac, and renal
function indices. Differences in clinical outcome com-
parators, including body composition analysis (water
balance) using bioimpedance, need for renal replacement
therapy, time on the ventilator, length of ICU and hos-
pital stay, as well as ICU and in-hospital mortality and
30-day and 90-day mortality, will also be analysed.
Methods
The “Hypertonic saline for fluid resuscitation after
cardiac surgery (HERACLES)” study is a single-centre
prospective double-blind randomised controlled clin-
ical trial taking place in a tertiary care university
hospital (Department of Intensive Care Medicine,
Inselspital, Bern University Hospital, University of
Bern, Switzerland). Recruitment started February 27,
2018 (ongoing); the current protocol version is V1.3,
dated March 1, 2018.
All patients undergoing cardiac surgery at our institu-
tion will be screened according to the predefined
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inclusion and exclusion criteria before written informed
consent is obtained. Prior to enrolment, the investigators
will explain to each participant the nature of the study,
its purpose, the procedures involved, the expected dur-
ation, and the potential risks and benefits. To give con-
sent to participate, the patient and the investigator or
his/her designee will sign an informed consent form
(ICF). Thereafter, the patient will be enrolled in the
study. Study procedures are performed according to the
planned schedule with adherence to visit intervals.
A Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist is provided in
Additional file 1. A schedule based on SPIRIT recom-
mendations is shown in Fig. 1.
Approvals
This study has been approved by the cantonal commit-
tee responsible for ethical research in humans (Kanto-
nale Ethikkommission, KEK, Bern, Switzerland, approval
number 2017-00647). Written informed consent will be
obtained from all participants.
Population
We aim to include a total of 96 patients (n = 48 per
group) undergoing elective cardiac surgery for ischaemic
and/or valvular heart disease and receiving the allocated
study investigational medicinal product (IMP).
Inclusion criteria
Patients aged ≥ 18 years who provide informed consent
meet the inclusion criteria.
Exclusion criteria
The exclusion criteria are as follows:
– Inability to provide informed consent
– Pregnancy or breastfeeding
– Preoperative left ventricular ejection fraction
(LVEF) < 30%
– Pre-existing renal insufficiency with an estimated
glomerular filtration rate (eGFR) < 30ml/min/1.73m2
– Postoperative mechanical circulatory support
devices such as left ventricular assist device (LVAD),
intra-aortic balloon pump (IABP), Impella, or extra-
corporeal membrane oxygenation (ECMO) device
– Pre-existing serum sodium level of > 145 mmol/L
or < 135 mmol/L
– Pre-existing serum chloraemia > 111 mmol/L or <
96mmol/L
– Systemic steroid therapy (at any dose at time of
inclusion)
Fig. 1 SPIRIT figure indicating visits and study-specific assessments
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– Chronic liver disease (bilirubin > 3 mg/dl)
– Any signs of infection or sepsis defined as clear
clinical evidence for active infection or current
antibiotic therapy
Randomisation and blinding
All patients undergoing cardiac surgery and meeting the
eligibility criteria as defined above will be enrolled in the
study and randomised to either the HS group (7.3%
NaCl) or the NS group (0.9% NaCl). Computerised ran-
domisation using a variable block size [2, 4, 6] will be
performed by a member of the study team not involved
in any part of treatment (neither nurse, resident, nor
supervisor). A box with the study vials and study infu-
sion will be given to the treating intensive care physician
with the patient’s number in the study. Participants, care
providers, investigators, and outcome assessors will be
blinded to study group assignment. A list for emergency
un-blinding of the study will be held by a designated
study quality manager.
Management of study material
Boxes with the study numbers containing unlabelled in-
fusions will be prepared for all patients prior to study
start. One box will contain a 1 × 500 ml + 1 × 100 ml
flask of 0.9% NaCl (B. Braun, Sempach, Switzerland) and
20 unlabelled vials of either 0.9% or 23.4% saline (Bich-
sel, Interlaken, Switzerland). For patients who weigh <
111 kg, 100 ml 0.9% NaCl of the 500-ml 0.9% NaCl flask
will be removed by syringe and 16 vials will be added to
the remaining 400 ml 0.9% NaCl, to create either a study
infusion of 0.9% saline or 7.3% saline.
For patients who weigh > 110 kg, we will prepare a
500-ml 0.9% NaCl flask as described for patients ≤ 110
kg and 1 ×100 ml 0.9% NaCl to which 4 vials of either
study infusion are added. All patients will receive 5ml/
kg of the study infusion over 60 min. The weight-
adjusted amount of study fluid will be prepared bedside
by the treating ICU nurse and given at 5 ml/kg body
weight over 60 min via infusion pumps through a central
venous line.
Study conduct
Patients included in the trial will receive standard moni-
toring for cardiac surgical patients in the ICU. We rou-
tinely monitor oxygen saturation, heart rate, invasive
arterial blood pressure, electrocardiography, temperature,
urine output, and central venous pressure.
Echocardiography will be performed preoperatively
and intraoperatively. If patients are considered haemo-
dynamically unstable, they receive a pulmonary artery
catheter (PAC) according to the hospital’s standard oper-
ating procedures (SOPs). Blood gas analysis parameters
and mixed venous oxygen saturation will be measured
according to clinical routine or as indicated at the dis-
cretion of the attending ICU physician.
General management
Maintenance of anaesthesia as well as haemodynamic
management during and after cardiopulmonary bypass
are standardised and protocol-driven according to the
hospital’s SOPs. All patients are sedated and ventilated
during transfer to the ICU. A blood gas analysis is per-
formed before the start of the study intervention and 1 h
after study infusion termination. Blood gas analyses are
performed every 2 h for the next 6 h and thereafter ac-
cording to clinical routine. Additionally, renal ultrason-
ography is performed to assess renal blood flow prior to
infusion as well as at 1 h and 2 h after termination of
the study fluid and on the first postoperative day.
Fluid management and haemodynamic protocol in the ICU
On admission to the ICU, patients will receive 5 ml/kg
ideal body weight of HS (7.3% NaCl) or NS (0.9% NaCl)
by infusion pump for 60 min. Thereafter, ICU treatment
will continue according to clinical routine.
If needed, norepinephrine is the first-choice vasopres-
sor and will be titrated to a mean arterial pressure
(MAP) judged adequate for the respective patient de-
pending on age and history of hypertension and kidney
injury. The range of target MAP is typically between 55
and 65mmHg. Epinephrine will be added when an add-
itional agent is needed to maintain adequate blood pres-
sure, and if necessary norepinephrine will be exchanged
for epinephrine. Dopamine is not used. In the presence
of myocardial dysfunction — as suggested by increased
cardiac filling pressures and low cardiac output — a do-
butamine infusion will be administered. If patients
become hypertensive, afterload will be reduced by nitro-
prusside natrium infusion.
Management of biological material
Two samples of blood as well as a urine sample will be
drawn and stored at − 80 °C at the four defined time
points (Fig. 1). Coded samples will be stored by the Cen-
ter of Laboratory Medicine, Inselspital, Bern University
Hospital, Switzerland.
Safety measures during study conduct
The infusion of HS can lead to several side effects in-
cluding electrolyte disturbances (hypernatraemia, hyper-
chloraemia, hypokalaemia), occurrence of acidosis, and
development of oedema. Hence the following safety
measures are taken: Before the start of the study inter-
vention, in the ICU a secondary screening will be per-
formed. First, a blood gas analysis will be done before
the start of the study intervention to ensure a serum so-
dium concentration postoperatively below 145mmol/L
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and a serum chloride concentration below 107mmol/L.
Second, a doctor of the research team will be contacted
if intraoperative complications such as massive bleeding,
severe haemodynamic turbulence, or intraoperative
myocardial infraction occurred. Based on the blood gas
analysis results and/or the medical history, it will be de-
cided if the study is to proceed. Patients admitted from
the ICU with cardiac assist devices such as an IABP or
an ECMO device or electrolyte levels outside the normal
range will be dropped from the study before receiving
the study intervention.
If the study is started, a blood gas analysis will be per-
formed 1 h after study infusion termination. For the first
20 patients we will perform a blood gas analysis after 30
min and 60 min of study infusion to check serum so-
dium levels; thereafter, if the sodium levels stay below
155mmol/L during infusion of the study fluid, this add-
itional blood gas analysis will be omitted. One hour after
termination of the study infusion an additional blood
gas analysis will be performed; thereafter, blood gas ana-
lyses will be performed every 2 h for the next 6 h and
thereafter according to clinical routine.
If the serum sodium level is above 155 mmol/L or the
serum chloride level is above 125mmol/L at any time
point, the infusion of the study medication will be
stopped.
Study parameters
We will obtain baseline data (age, gender, height, weight,
BMI), baseline comorbidities, risk scores, and preopera-
tive and postoperative routine laboratory parameters in
all patients. Additionally we will perform sonographic
assessment of renal blood flow and assess body compos-
ition (bioimpedance) at predefined endpoints.
All types of fluids and the cumulative amounts (blood
products included), daily body weight, and cumulative
doses of medication will be documented. Furthermore,
the need for renal replacement therapy, length of mech-
anical ventilation, length of ICU and hospital stays, and
mortality will be assessed.
Outcome measures
Primary endpoint
The primary endpoint is the difference in total cumula-
tive fluid volume administered during ICU stay between
patients receiving HS and patients receiving NS follow-
ing elective cardiac surgery.
Secondary endpoints
Secondary endpoints are to investigate whether use of
HS results in:
– Reduced cumulative vasopressor dose and shorter
time on vasopressors after cardiac surgery
- Differences in urinary output and postoperative
weight gains between the two groups.
Exploratory outcomes
Exploratory outcomes are to assess whether the use of
HS results in:
– A change in acid-base parameters and electrolyte
levels as well as inflammatory/immune function
indices
– Differences in clinical outcome comparators,
including body composition analysis (water balance)
using bioimpedance, need for renal replacement
therapy, time on the ventilator, length of ICU and
hospital stays, as well as ICU mortality and in-
hospital mortality. We will also analyse 30-day and
90-day mortality.
Study timetable
The timing of assessment of study parameters is out-
lined in Fig. 1.
End of study
For included patients, the study will start with admission
to the ICU and will end after day 6. Thereafter, patients
will be followed up for secondary endpoints. Patients
will not be monitored further if they are readmitted to
the ICU.
Statistics
Statistical evaluation will be conducted in the intent-to-
treat population (carry forward last value method).
Descriptive presentation of the recorded data will be
based on a scale type. Nominal/ordinal scales include
cell frequencies at each level, missing data, valid number,
and total number. Interval/proportional scales include
arithmetic mean, standard deviation, median, spread,
minimum, maximum, and valid number. In addition to
the summary of the data using statistical parameters, de-
scriptions will be provided individually for the total
population as well as for both groups.
Statistical methods
This is a classic two-group study with parallel groups.
Whether HS results in less total fluid volume will be
assessed by the Mann-Whitney U test. Interval vari-
ables between groups will be compared using Stu-
dent’s t test or the Mann-Whitney U test as
appropriate. Fisher’s test for exact probability will be
used for the nominal scale data. In the event of an
uneven baseline situation, multivariable regression
(linear regression for interval outcomes and logistic
regression for dichotomous outcomes) will be used
for adjustment of baseline differences.
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Estimation of sample size
Sample size calculation was based upon fluid data from
the Hemacetat study (NCT02895659) [28], conducted at
our institution with the same patient collective. Prelim-
inary data showed that patients received a mean of 3381
ml fluid during their ICU stay, with a standard deviation
of 1734ml. A clinically relevant effect size was deter-
mined to be a reduction of 1000ml fluid (30%).
Rationale for effect size
Although several studies reported reduced infusion vol-
umes when HS was used for fluid resuscitation [29],
there is a large heterogeneity in studies on HS use, with
widely varying amounts of sodium administered. In con-
sequence, it was not possible to determine the amount
of fluid to be saved when HS is used based on the avail-
able literature. Fluid overload is harmful in patients
undergoing cardiac surgery and related to adverse out-
comes [30–32] and thus should be avoided. However,
the ideal amount of fluid for these patients is not yet
clarified. In a pragmatic approach, we hence deter-
mined that it would be clinically beneficial if the total
amount of fluid administered intravenously in the
ICU (average 3381 ml at our institution) could be
lowered by 1 L or 30%.
Modelling based on values of this study was achieved
with the Power and Sample Size Calculator provided by
the Statistical Institute of the Medical University of
Vienna (http://statistics.msi.meduniwien.ac.at) and
cross-checked on http://powerandsamplesize.com. The
following constellations were obtained with regard to
the required case numbers: n = 48 with a power of 80%
and an α error of 0.05. Based on these results, a number
of n = 48 patients with an IMP for each group, for a total
number of 96 patients with an IMP, was determined to
be sufficient.
Ethical considerations
The study will be carried out in accordance with the
protocol and with principles enunciated in the current
version of the Declaration of Helsinki and the Inter-
national Conference on Harmonisation (ICH) guidelines
for Good Clinical Practice (GCP). The KEK and regula-
tory authorities will receive annual safety and interim re-
ports and be informed if the study is discontinued, in
agreement with local requirements. The KEK will be in-
formed within 90 days if the study is discontinued.
All patients must give consent to participate in the
study after receiving a detailed explanation of the poten-
tial benefits and harms. Patient information material as
well as the consent form are included in the appendix of
the study protocol. The KEK will receive a final report
within 1 year of study termination.
Premature study termination
The sponsor or investigator may terminate the study
prematurely for a variety of reasons, including unfore-
seen ethical concerns, insufficient participant recruit-
ment, doubts about the safety of the participants, or
alterations in accepted clinical practice that make the
continuation of a clinical trial unwise. For patients
already enrolled in the study, treatment will be stopped
immediately, while patient data will be recorded and ob-
served until the patient leaves the ICU.
If the study has to be terminated prematurely, the
regulatory authorities will be informed within 15 days.
Data management
Monitoring
Data will be obtained, recorded, and safely stored in real
time by the clinic’s patient monitoring system. Quality
assurance will be provided by professional full-time
study nurses. Informed consent sheets, randomisation,
and case report form completeness will be checked.
Study documentation and data will be accessible to audi-
tors/inspectors from the KEK and other regulatory au-
thorities at any time. All parties involved will keep
individual data strictly confidential.
Data storage
Data will be stored for 10 years in accordance with Swiss
law.
Publication
The authors plan to publish the results of the study in a
peer-reviewed journal. Authorship will be granted based
on International Committee of Medical Journal Editors
(ICMJE) definitions.
Discussion
Patients undergoing cardiac surgery typically receive a
significant amount of intravenous fluids to support cir-
culatory function and counteract the side effects of
rewarming after cardiopulmonary bypass [10]. In cardiac
surgery patients, the influence of crystalloid solutes on
the acid-base status, intracellular and extracellular water
content, and plasma electrolyte composition has a sub-
stantial impact on organ function and outcome [33–35].
Additionally, changes in vascular permeability and onco-
tic pressure contribute to fluid leakage [36]. Therefore,
these patients typically suffer from various degrees of
fluid overload after prolonged ICU stay [10]. Fluid over-
load has previously been associated with increased mor-
tality and morbidity in various subgroups of critically ill
patients [37–39].
Preliminary data from a study conducted recently in our
institution showed that fluid balance on the first postoper-
ative day is around plus 6500ml [40]. Therefore, the
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exploration of alternative fluid resuscitation strategies for
patients after cardiac surgery in order to minimise fluid
overload seems of paramount importance.
Previous data suggest that HS might be a safe alterna-
tive for fluid resuscitation in patients for whom fluid
overload should be avoided [27]. However, data on the
use of HS for this indication are scarce: Only five studies
have assessed volume status as a primary target criterion
after infusion of HS [22, 27, 41–43], with only one study
being performed in patients after cardiac surgery [27].
The latter was a randomised controlled double-blind
trial involving 72 post-cardiac surgical patients [27].
Endpoints of this study were postoperative weight gain
as well as total volume balance when fluid resuscitation
with 0.9% saline was compared to a bolus of 4 ml/kg
7.5% saline plus 0.9% saline [27]. The study showed a
promising 10% reduction in total volume need, a 50% in-
crease in 1-h urine production, and a 50% reduction of
perioperative weight gain [27]. Nonetheless, the results
of this study have not been confirmed so far.
In addition, other authors have assessed HS in various
settings. Two of these studies investigated HS for pre-
loading before spinal anaesthesia [22, 41]. Veroli and
colleagues conducted a study in 30 patients, classified as
American Society of Anesthesiologists (ASA) category I,
who were undergoing minor orthopaedic surgery under
spinal anaesthesia. Patients received HS (5%), NS, or
dextrose 5% for fluid preloading (2 mmol sodium/kg)
[41]. Preloading with HS resulted in less total intraoper-
ative fluid volume administered [41]. Jarvela and co-
workers conducted a randomised double-blind study to
evaluate the effects of 7.5% HS on extracellular water
volume and hematocrit in patients undergoing arthros-
copy or other lower limb surgery under spinal anaesthe-
sia [22]. A total of 40 patients were included in the
study; they received 1.6 ml/kg of HS or 13ml/kg of NS
for preloading before spinal anaesthesia [22]. Total infu-
sion volume was markedly lower in the HS group, but
haemodynamic indices remained comparable between
groups [22]. The authors concluded that HS may be a
safe alternative in patients in whom fluid overload
should be avoided [22].
Two additional studies targeted patients with volume
overload [42, 43]. Paterna and Parrinello performed two
randomised controlled trials involving patients with
chronic heart failure with New York Heart Association
(NYHA) classification III/IV [42, 43]. Patients in respect-
ive studies received either HS twice daily with 250 mg
furosemide or furosemide only for treatment of fluid
overload [42]. Patients in the HS group showed a signifi-
cant increase in diuresis, reduction in whole body water
content, and significant improvement in NYHA class
and ejection fraction as assessed by echocardiography
[42, 43]. Serum creatinine and blood urea nitrogen
(BUN) increased in the control group, whereas they de-
creased in the HS group [42, 43]. Additionally, hospital-
isation time, readmission rate, and mortality rates were
reduced in the HS group [42, 43].
We thus are conducting this randomised double-blind
controlled clinical trial to test the hypothesis that use of
HS results in less total volume infused and less postop-
erative weight gain when compared to standard of care
in post cardiac surgery patients.
Strengths and limitations
To our knowledge, this is the first randomised con-
trolled trial comparing two different saline solutions
(7.3% versus 0.9%) in cardiac surgical patients in the
ICU. The preliminary character of the study will allow
further hypothesis generation in other areas, such as
emergency cardiac surgery or sepsis.
Because this study will be performed at a single ter-
tiary care centre, the external validity is limited. In
addition, note that this is a preliminary study, so the
number of patients included is limited. A further limita-
tion of our study arises from the exclusion of sick
patients.
Trial status
The trial protocol and schedule are as follows:
 Protocol version: V1.3, March 1, 2018
 2016–2017: Finalisation of research strategy,
finalisation of protocol, approvals
 2017–2018: Funding obtained
 2018–2019: First patient enrolled (February 27,
2018); end of trial predicted for the end of 2019
 2020: Analysis of trial results and publication
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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